Literature DB >> 14764694

Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection.

Laura Gibson1, Giampiero Piccinini, Daniele Lilleri, Maria Grazia Revello, Zhongde Wang, Susan Markel, Don J Diamond, Katherine Luzuriaga.   

Abstract

Recombinant modified vaccinia Ankara- and peptide-based IFN-gamma ELISPOT assays were used to detect and measure human CMV (HCMV)-specific CD8(+) T cell responses to the pp65 (UL83) and immediate early protein 1 (IE1; UL123) gene products in 16 HCMV-infected infants and children. Age at study ranged from birth to 2 years. HCMV-specific CD8(+) T cells were detected in 14 (88%) of 16 children at frequencies ranging from 60 to >2000 spots/million PBMC. Responses were detected as early as 1 day of age in infants with documented congenital infection. Nine children responded to both pp65 and IE1, whereas responses to pp65 or IE1 alone were detected in three and two children, respectively. Regardless of the specificity of initial responses, IE1-specific responses predominated by 1 year of age. Changes in HCMV epitopes targeted by the CD8(+) T cell responses were observed over time; epitopes commonly recognized by HLA-A2(+) adults with latent HCMV infection did not fully account for responses detected in early childhood. Finally, the detection of HCMV-specific CD8(+) T cell responses was temporally associated with a decrease in peripheral blood HCMV load. Taken altogether, these data demonstrate that the fetus and young infant can generate virus-specific CD8(+) T cell responses. Changes observed in the protein and epitope-specificity of HCMV-specific CD8(+) T cells over time are consistent with those observed after other primary viral infections. The temporal association between the detection of HCMV-specific CD8(+) T cell responses and the reduction in blood HCMV load supports the importance of CD8(+) T cells in controlling primary HCMV viremia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764694     DOI: 10.4049/jimmunol.172.4.2256

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

Review 1.  CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model.

Authors:  Rafaela Holtappels; Verena Böhm; Jürgen Podlech; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2008-03-15       Impact factor: 3.402

2.  Limits and patterns of cytomegalovirus genomic diversity in humans.

Authors:  Nicholas Renzette; Cornelia Pokalyuk; Laura Gibson; Bornali Bhattacharjee; Mark R Schleiss; Klaus Hamprecht; Aparecida Y Yamamoto; Marisa M Mussi-Pinhata; William J Britt; Jeffrey D Jensen; Timothy F Kowalik
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-06       Impact factor: 11.205

3.  Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine.

Authors:  Peter A Gillis; Nelmary Hernandez-Alvarado; Josephine S Gnanandarajah; Felix Wussow; Don J Diamond; Mark R Schleiss
Journal:  Vaccine       Date:  2014-05-20       Impact factor: 3.641

4.  Longitudinal Kinetics of Cytomegalovirus-Specific T-Cell Immunity and Viral Replication in Infants With Congenital Cytomegalovirus Infection.

Authors:  Sharon F Chen; Tyson H Holmes; Teri Slifer; Vasavi Ramachandran; Sally Mackey; Cathleen Hebson; Ann M Arvin; David B Lewis; Cornelia L Dekker
Journal:  J Pediatric Infect Dis Soc       Date:  2014-09-11       Impact factor: 3.164

5.  Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation.

Authors:  Lei Bao; Kimberly Dunham; Mindy Stamer; Kevin M Mulieri; Kenneth G Lucas
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

6.  The essential role of guinea pig cytomegalovirus (GPCMV) IE1 and IE2 homologs in viral replication and IE1-mediated ND10 targeting.

Authors:  Julia Hornig; K Yeon Choi; Alistair McGregor
Journal:  Virology       Date:  2017-02-10       Impact factor: 3.616

7.  CD4+ T-cell reconstitution reduces cytomegalovirus in the immunocompromised brain.

Authors:  Jon D Reuter; Jean H Wilson; Kimberly E Idoko; Anthony N van den Pol
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

8.  DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus.

Authors:  Anna Gil; Siyuan Shen; Scott Coley; Laura Gibson; Don J Diamond; Shixia Wang; Shan Lu
Journal:  Hum Vaccin Immunother       Date:  2013-07-25       Impact factor: 3.452

9.  Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection.

Authors:  Matthew R Pipeling; Erin E West; Christine M Osborne; Amanda B Whitlock; Lesia K Dropulic; Matthew H Willett; Michael Forman; Alexandra Valsamakis; Jonathan B Orens; David R Moller; Noah Lechtzin; Stephen A Migueles; Mark Connors; John F McDyer
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  Identification of HLA-A*2402-restricted HCMV immediate early-1 (IE-1) epitopes as targets for CD8+ HCMV-specific cytotoxic T lymphocytes.

Authors:  Jong-Baeck Lim; Hyun Ok Kim; Seok Hoon Jeong; Joo Eun Ha; Sunphil Jang; Sang-Guk Lee; Kyungwon Lee; David Stroncek
Journal:  J Transl Med       Date:  2009-08-23       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.